S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
5 Stocks to Buy Immediately (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
5 Stocks to Buy Immediately (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
5 Stocks to Buy Immediately (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
5 Stocks to Buy Immediately (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
5 Stocks to Buy Immediately (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
5 Stocks to Buy Immediately (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
5 Stocks to Buy Immediately (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
5 Stocks to Buy Immediately (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
5 Stocks to Buy Immediately (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
5 Stocks to Buy Immediately (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
5 Stocks to Buy Immediately (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
5 Stocks to Buy Immediately (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
NASDAQ:CMRX

Chimerix - CMRX Stock Forecast, Price & News

$1.26
+0.05 (+4.13%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.22
$1.29
50-Day Range
$1.19
$1.84
52-Week Range
$1.18
$5.39
Volume
539,190 shs
Average Volume
853,634 shs
Market Capitalization
$111.22 million
P/E Ratio
0.64
Dividend Yield
N/A
Price Target
$8.50

Chimerix MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
574.6% Upside
$8.50 Price Target
Short Interest
Bearish
4.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.49
Upright™ Environmental Score
News Sentiment
0.44mentions of Chimerix in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$24,200 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.85) to ($0.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

105th out of 1,004 stocks

Pharmaceutical Preparations Industry

39th out of 489 stocks


CMRX stock logo

About Chimerix (NASDAQ:CMRX) Stock

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

CMRX Stock News Headlines

Where Are The Markets Going Next?
More banking collapses could be imminent. If you have any money (at all) invested in the markets... even just your retirement... you'll want to see THIS. What we reveal now could help you sooner (and you won’t want it to be later). pixel
Chimerix's Earnings Outlook
JonesTrading Keeps Their Buy Rating on Chimerix (CMRX)
Unusual Passive Income Investment (Found on a Golf Course)
Marc reveals how anyone can get into a similar opportunity for just $5.
Why Chimerix (CMRX) Stock Is Tanking Today
Hedge fund urges Durham drugmaker Chimerix to liquidate
Chimerix Responds to Rubric Capital Management
Buy 3 of the Best Stocks by Using Net Income Ratio
Chimerix (CMRX) Beats Q3 Earnings Estimates
See More Headlines
Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

CMRX Company Calendar

Last Earnings
3/02/2023
Today
3/31/2023
Next Earnings (Estimated)
5/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMRX
Employees
87
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$8.50
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+574.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$172.17 million
Pretax Margin
509.11%

Debt

Sales & Book Value

Annual Sales
$33.82 million
Cash Flow
$2.07 per share
Book Value
$2.92 per share

Miscellaneous

Free Float
81,036,000
Market Cap
$111.22 million
Optionable
Optionable
Beta
1.18

Social Links


Key Executives

  • Michael A. Sherman
    President, Chief Executive Officer & Director
  • Michael T. Andriole
    Chief Financial & Business Officer
  • Roy W. Ware
    Chief Technology & Manufacturing Officer
  • Caryn Barnett
    Vice President-Clinical Operations
  • Allen Melemed
    Chief Medical Officer













CMRX Stock - Frequently Asked Questions

Should I buy or sell Chimerix stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings
or view top-rated stocks.

What is Chimerix's stock price forecast for 2023?

3 Wall Street research analysts have issued 1-year price targets for Chimerix's stock. Their CMRX share price forecasts range from $6.00 to $11.00. On average, they anticipate the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 574.6% from the stock's current price.
View analysts price targets for CMRX
or view top-rated stocks among Wall Street analysts.

How have CMRX shares performed in 2023?

Chimerix's stock was trading at $1.86 at the beginning of 2023. Since then, CMRX stock has decreased by 32.3% and is now trading at $1.26.
View the best growth stocks for 2023 here
.

Are investors shorting Chimerix?

Chimerix saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 3,290,000 shares, an increase of 17.5% from the February 28th total of 2,800,000 shares. Based on an average daily trading volume, of 745,700 shares, the short-interest ratio is currently 4.4 days. Currently, 4.4% of the company's stock are short sold.
View Chimerix's Short Interest
.

When is Chimerix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our CMRX earnings forecast
.

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) released its earnings results on Thursday, March, 2nd. The biopharmaceutical company reported ($0.24) EPS for the quarter, meeting analysts' consensus estimates of ($0.24). The biopharmaceutical company earned $0.81 million during the quarter, compared to the consensus estimate of $2.60 million. Chimerix had a trailing twelve-month return on equity of 113.54% and a net margin of 509.01%. During the same quarter in the previous year, the company posted ($0.45) earnings per share.

What ETFs hold Chimerix's stock?

ETFs with the largest weight of Chimerix (NASDAQ:CMRX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).ETFMG Treatments Testing and Advancements ETF (GERM).

What other stocks do shareholders of Chimerix own?
What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Who are Chimerix's major shareholders?

Chimerix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (3.63%), Monaco Asset Management SAM (2.62%), AQR Capital Management LLC (1.92%), Geode Capital Management LLC (1.79%), Millennium Management LLC (1.46%) and Morgan Stanley (0.88%). Insiders that own company stock include David Jakeman, Fred A Middleton, Martha J Demski, Michael T Andriole and Robert J Meyer.
View institutional ownership trends
.

How do I buy shares of Chimerix?

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $1.26.

How much money does Chimerix make?

Chimerix (NASDAQ:CMRX) has a market capitalization of $111.22 million and generates $33.82 million in revenue each year. The biopharmaceutical company earns $172.17 million in net income (profit) each year or $1.96 on an earnings per share basis.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The official website for the company is www.chimerix.com. The biopharmaceutical company can be reached via phone at (919) 806-1074, via email at ir@chimerix.com, or via fax at 919-806-1146.

This page (NASDAQ:CMRX) was last updated on 4/1/2023 by MarketBeat.com Staff